Does Lilly need Genzyme more than Sanofi?

Eli Lilly's latest pipeline setback for Alzheimer's is adding extra pressure on CEO John Lechleiter to do something dramatic to quickly improve the pharma company's product mix. And that has BNET's Jim Edwards speculating that Lilly should jump in with a better offer for Genzyme, shoving Sanofi aside. After all, over the next four years Lilly faces the loss of patents on drugs that account for 60 percent of its revenue. And Effient has been a bust. The reasoning may be based on nothing but a few facts about Lilly's conundrum tied to Edwards' fertile imagination, but it makes for a fun read. Report